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Abstract
Background: Lipocalin 2, an iron binding protein, is abnormally expressed in some malignant
human cancers and may play an important role in tumor metastasis. However, the roles of lipocalin
2 in breast cancer formation and metastasis have not been clearly shown. This study aimed to
investigate the roles of lipocalin 2 in breast tumor metastasis.
Methods: Lipocalin 2 was overexpressed in the metastatic 4T1 murine mammary cancer cells. The
effects of lipocalin 2 overexpression on the malignancy of breast cancer cells were examined using
cell proliferation assay, migration assay, invasion assay, and soft agar assay in vitro. Tumor formation
and metastasis abilities were examined using a well established mouse mammary tumor model in
vivo.
Results: Lipocalin 2 overexpression significantly enhanced the migration and invasion abilities of
4T1 cells in vitro, and lung metastasis in vivo. But overexpression of lipocalin 2 in 4T1 cells didn't
affect cell proliferation and anchorage-independent growth in vitro, and primary tumor weight in
vivo. Further studies demonstrated that the inhibition of the PI3K/Akt pathway could be a causative
mechanism for the promotion of breast cancer migration/invasion induced by lipocalin 2
overexpression.
Conclusion: These results clarified that lipocalin 2 could promote lung metastasis of 4T1 cells
through the inhibition of the PI3K/Akt pathway, suggesting that lipocalin 2 was a potential target
for therapy of breast cancer.
Background
Lipocalins are a diverse family of over 20 small soluble,
and often secreted, proteins. There is increasing evidence
to claim that these proteins as transporters are involved in
a variety of physiological functions. These functions
include the regulation of immune responses, modulation
of cell growth and metabolism, transportation of iron and
prostaglandin synthesis [1]. Human NGAL (neutrophil
gelatinase-associated lipocalin) and its mouse analogue
lipocalin 2 (also referred to as siderocalin, Ngal, 24p3,
uterocalin, or neu-related lipocalin) are members of the
lipocalin family of small secreted proteins [2]. These pro-
teins are up-regulated in a number of pathological condi-
tions, including cancers, and may function as transporters
of essential factors. Mouse lipocalin 2 was originally
cloned from mouse kidney cells infected with polyoma
virus-40 [3]. Yang et al. found lipocalin 2 could bind to
iron and then deliver it to the cell through a process
requiring endocytosis [4]. Subsequently, lipocalin 2 cell-
surface receptor 24p3R was identified [5]. Moreover,
Published: 12 December 2008
Journal of Experimental & Clinical Cancer Research 2008, 27:83 doi:10.1186/1756-9966-27-83
Received: 12 October 2008
Accepted: 12 December 2008
This article is available from: http://www.jeccr.com/content/27/1/83
© 2008 Shi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Experimental & Clinical Cancer Research 2008, 27:83 http://www.jeccr.com/content/27/1/83
Page 2 of 9
(page number not for citation purposes)
lipocalin 2 was induced by lipopolysaccharide [6], basic
fibroblast growth factor [7], tumor necrosis factor α [8]
and retinoic acid [9]. Until now, growing evidence sug-
gests that lipocalin 2 plays an important role in innate
immune response, cell apoptosis and tumor development
[10].
In human, elevated levels of lipocalin 2 expression have
been reported in various cancers including ovarian cancer,
pancreatic cancer, lung cancer, colon cancer and breast
cancer, indicating there is a strong association between
lipocalin 2 and the malignance of cancer cells and that
metastasis [11]. It was found that NGAL/lipocalin 2 was
overexpressed in the progression of malignant transfor-
mation from human immortalized esophageal epithelial
cell line SHEE to esophageal carcinoma cell line SHEEC
[12]. Moderate to strong expression of NGAL/lipocalin 2
was observed in epithelial ovarian cancer cell lines SKOV3
and OVCA433 while no expression of NGAL/lipocalin 2
was evident in normal IOSE29 and mesenchyme-like
OVHS1, PEO.36 and HEY cell lines [13]. A study of Fern-
andez et al. demonstrated that in MCF-7 human breast
cancer cells lipocalin 2 could enhance tumor growth and
metastasis by protecting matrix metalloproteinase-9
(MMP-9) from degradation and increasing angiogenesis.
And, the MMP-9/lipocalin 2 complexes were detected in
90% of urine samples obtained from breast cancer
patients, but not in those from healthy controls [14].
Besides that, cell lines derived from highly metastatic
breast cancer, such as MDA-MB-231, expressed and
secreted higher amounts of NGAL/lipocalin 2 than cell
lines derived from benign, organ defined breast cancers
[15].
Mouse lipocalin 2 is overexpressed in oncogene-mediated
cell transformation [16]. Under normal conditions,
expression of lipocalin 2 is restricted to breast [17]; how-
ever, increased lipocalin 2 levels have been reported in
breast cancer [18]. Although lipocalin 2 have been dem-
onstrated to correlate with breast cancer [19], the roles of
lipocalin 2 in breast cancer formation and metastasis have
not been clearly shown. In this study, we overexpressed
lipocalin 2 in 4T1 mouse mammary tumor cells, and
investigated the effects and molecular mechanisms of
lipocalin 2 on breast tumor malignant properties.
Methods
Cells and cell culture
4T1 is mouse mammary tumor cell line [20], which was
kindly provided by Dr. Fred R. Miller at the Karmanos
Cancer Institute in Detroit, MI. 4T1 is cultured in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal calf serum (DME-10), 1 mM mixed nones-
sential amino acids, and 2 mM L-glutamine.
Plasmid construction and establishment of stable 
transfectants
To create the mouse lipocalin 2 overexpression vector,
full-length lipocalin 2 encoding gene was amplified from
the total RNA of 4T1 cells with RT-PCR (the cloning
primer: lipocalin2F: 5'-GAAGATCTATGGCCCTGAGTGT-
CATGTG-3', lipocalin2R: 5'-GGAATTCTCAGTTGTCAAT-
GCATTGG-3'). The gene was then digested by BglII/EcoRI
and inserted into BglII/EcoRI double digested pMSCVpuro
(a self-inactivating murine stem cell virus plasmid) vector,
resulting in the lipocalin 2 retroviral expression vector,
pMSCVpuro-lipocalin2.
Retrovirus was produced in the Phoenix packaging cell
line. In brief, Phoenix cells were plated at 2 × 106 cells/
well in 60-mm plates and allowed to adhere overnight.
The cells were separately transfected with the pMSCVpuro
or pMSCVpuro-lipocalin2 plasmid (10 μg/plate) by CaCl2
transfection. Replication retrovirus was harvested 48
hours after transfection, sterile filtered to remove nonad-
herent producer cells, and then infected 4T1 cells sepa-
rately. Infected cells were cultured in medium with 4 μg/
ml puromycin for 2 weeks. The resistant clones were iso-
lated by limit dilution and dispatched in new dishes.
Then, the obtained cells were named Mock and lipocalin
2 (LCN2) respectively.
RNA isolation and semiquantitative RT-PCR (Reverse 
transcription polymerase chain reaction)
Total RNA was isolated from cells using Trizol (Invitro-
gen, Carlsbad, CA, USA) and reverse transcription was car-
ried out using High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA). The relative quantita-
tive analysis was normalized to endogenous control β-
actin. Mouse lipocalin 2 forward primer was 5'-TGCAG-
GTGGTACGTTGTGG-3', and its reverse primer was 5'-
TGTTGTCGTCCTTGAGGC-3'. Mouse β-actin forward
primer was 5'-ATCTGGCACCACACCTTCTAC-3', and its
reverse primer was 5'-CACACTTCATGATGGAATTGAA-3'.
Cell proliferation assay
Cells were seeded 1 × 104 per well in a 96-well plate. Cells
were allowed to grow for 24 hours. Then, 20 μl of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (5 mg/ml) was added to each well. After 4 hours of
incubation at 37°C, cells were lysed by addition of 200 μl
dimethylsulfoxide (DMSO). Absorbance was measured at
570 nm using a Rainbow microplate reader (Tecan, Grod-
ing/Salzburg, Austria).
Assays for soft agar colony
Colony formation in soft agar was assessed as described
[21]. Cells (5 × 103) from Mock and LCN2 were sus-
pended in 1 ml top agar medium (DME-10 supplied with
0.4% agar), in the presence or absence of phosphoi-Journal of Experimental & Clinical Cancer Research 2008, 27:83 http://www.jeccr.com/content/27/1/83
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nositide-3 kinase (PI3K)-specific inhibitor LY294002
(Merck, Nottingham, UK), and layered over 1.5 ml bot-
tom agar medium (DME-10 supplied with 0.8% agar) in
35-mm dishes. After 3 weeks, the cells were photographed
under inverted microscope and the number of colonies
was counted. Independent experiments were performed
in triplicates.
In vitro migration assay and invasion assay
Cell migration was assayed using Transwell chambers (6.5
mm; Corning, New York, USA) with 8 μm pore mem-
branes. The lower chamber was filled with 600 μl NIH-
3T3 conditioned medium [22] containing 20 μg/ml
fibronectin (BD Biosciences, Bedford, MA, USA) with or
without 2 μM LY294002. Cells (5 × 104) were suspended
with 100 μl upper medium (DMEM with 1% fetal calf
serum) and planted into the upper chamber with or with-
out 2 μM LY294002. After 16 hours, the number of cells
appearing by crystal violet staining on the undersurface of
the polycarbonate membranes was scored visually in five
random fields at 100× magnification using a light micro-
scope.
For invasion assay, the upper face of the membrane was
covered with 70 μl Matrigel (1 mg/ml; BD Biosciences).
The invasion assay procedure was the same as for the
migration assay, except that the incubation time of the
experiment was prolonged to 24 hours.
Primary tumor growth and lung metastases assay
These procedures were performed as described previously
[20,23] with minor modifications. Female BALB/c mice,
aged 8 to 10 weeks, were used in the experiment. In brief,
mice (six to eight per group) were anesthetized with
sodium pentobarbital (50 mg/kg body weight), and
tumor cells (5 × 105) in 10 μl DME-10 were injected into
the mammary gland. The weight of the primary tumors
and the number of metastatic nodules on the lung surface
were evaluated 30 days after the tumor cells injection. The
animals were housed and cared for in accordance with the
guidelines established by the National Science Council of
Republic of China.
Immunoprecipitation (IP) and Immunoblotting (IB) 
analysis
Cells were lysed in lysis buffer (50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 1% NP40, 1 mM EDTA, 1 mM Na3VO4, 10
mM NaF) containing a protease inhibitor cocktail (Roche,
Nutley, NJ, USA). Protein samples (50 μg) were separated
by 12% SDS-PAGE and transferred to Immobilon-P mem-
branes (Millipore, Bedford, MA, USA). Antibodies to
phosphorylated and total Akt (Cell Signaling, Beverly,
MA, USA), phosphorylated (Ser380/Thr382/383) and
total PTEN (Cell Signaling), phosphorylated (Thr202/
Tyr204) and total MAPK (Cell Signaling), and β-Actin
(Santa Cruz, CA, USA) were used, with detection by ECL-
detecting reagent (Amersham Biosciences, Buckingham-
shire, UK). Quantification of the blots was conducted
using Image-Pro Plus software (version 6.0; Media Cyber-
netics, Bethesda, MD, USA).
For immunoprecipitation assay, after cells were cultured
for 48 hour, we collected 1 ml of the DMEM medium for
immunoprecipitation with anti-mouse lipocalin 2 mono-
clonal antibody (Santa Cruz). The following procedure
was the same as IB.
Statistic analysis
All of the results were repeated in at least three independ-
ent experiments and consistently yielded similar results.
Data was presented as mean ± SD. Statistical significance
was analyzed using the SPSS 11.0 software program (SPSS
Inc., Chicago, IL, USA). The value of P < 0.05 was consid-
ered statistically significant.
Results
Overexpression of lipocalin 2 gene in 4T1 cell line
To determine whether lipocalin 2 played an important
role in tumor metastasis, lipocalin 2 gene was stably over-
expressed in 4T1 cell line. As shown in Figure 1A, the
expression of lipocalin 2 mRNA was increased obviously
in 4T1 cells infected with pMSCVpuro-lipocalin2 (LCN2),
compared to that in 4T1 cells infected with pMSCVpuro
(Mock); and the secreted lipocalin 2 level was increased
significantly in the conditional medium of LCN2 (Figure
1B).
Effects of lipocalin 2 on proliferation and anchorage-
independent growth of 4T1 cells
To investigate whether lipocalin 2 overexpression in 4T1
cells affected their proliferation, MTT assay was per-
formed. As shown in Figure 2A, lipocalin 2 did not affect
the proliferation of 4T1 cells. As anchorage-independent
growth measured by colony formation in a semi-solid
medium was thought to be one of the fundamental prop-
erties of malignant cells, we further investigated the ability
of anchorage-independent growth. The result indicated
that LCN2 cells and Mock cells formed the same colonies
(Figure 2B).
Lipocalin 2 enhances migration and invasion of 4T1 cells in 
vitro
To investigate the role of lipocalin 2 in 4T1 cells metasta-
sis, we determined the effects of lipocalin 2 on the migra-
tion and invasion of 4T1 cells in vitro. As shown in Figure
3, the overexpression of lipocalin 2 significantly pro-
moted 4T1 cells migration and invasion.
Lipocalin 2 promotes lung metastases of 4T1 cells in vivo
Based on the roles of lipocalin 2 in the migration and
invasion of 4T1 cells as described above, we next exam-
ined the effects of lipocalin 2 on tumor formation andJournal of Experimental & Clinical Cancer Research 2008, 27:83 http://www.jeccr.com/content/27/1/83
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metastasis in vivo. The results demonstrated that lipocalin
2 dramatically increased the number of visible metastatic
nodules on the lung surface of tumor-bearing mice (Fig-
ure 4A), but had no effect on the primary tumor weight
(Figure 4B). Then the expression level of lipocalin 2 in pri-
mary tumors was investigated. Consistent with the results
in Figure 1A, Figure 4C showed that the expression of
lipocalin 2 in LCN2 tumors was higher than that in Mock
tumors. These results indicated that lipocalin 2 remained
stable in both Mock and LCN2 tumors, and had no effect
on tumor growth.
Lipocalin 2 promotes breast cancer cells migration and 
invasion through PI3K/Akt pathway
To investigate the molecular mechanism of lipocalin 2-
mediated cells migration and invasion, some tumor
metastasis-associated proteins and signaling pathways
were assayed by IB. As shown in Figure 5, the overexpres-
sion of lipocalin 2 significantly decreased the phosphor-
ylation of Akt at two key residues Thr308 and Ser473
(Figure 5A), and increased the phosphorylation of PTEN
in 4T1 cells (Figure 5B); however, the overexpression of
lipocalin 2 did not affect the expression and phosphoryla-
tion of MAPK (Figure 5C).
Finally, we evaluated whether signaling through the PI3K/
Akt pathway impacted cell migration/invasion. The
results showed that PI3K specific inhibitor LY294002 (2
μM) accelerated migration/invasion of Mock cells, similar
to the effects induced by lipocalin 2 overexpression (Fig-
ure 5D and 5E). These results suggested that lipocalin 2
overexpression could cause an increase of PTEN activation
Overexpression of lipocalin 2 in 4T1 cells Figure 1
Overexpression of lipocalin 2 in 4T1 cells. (A) Upper 
panels: semiquantitative RT-PCR analysis of lipocalin 2 
mRNA expression in LCN2 and Mock cells. Lower panels: 
quantitation of lipocalin 2 after normalization with the β-
actin. (B) Western blotting analysis was performed with anti-
body recognizing mouse lipocalin 2. **P < 0.01.
Analysis of proliferation and anchorage-independent growth  of 4T1 cells Figure 2
Analysis of proliferation and anchorage-independent 
growth of 4T1 cells. (A) The proliferation of lipocalin 2 
overexpressed 4T1 cells was analyzed by MTT assay. (B) 
Anchorage-independent growth of lipocalin 2 overexpressed 
4T1 cells was analyzed by soft agar assay.Journal of Experimental & Clinical Cancer Research 2008, 27:83 http://www.jeccr.com/content/27/1/83
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and result in the inhibition of Akt signaling, which pro-
moted cell migration and invasion.
PI3K/Akt pathway has no effect on anchorage-
independent growth of breast tumor cells
To determine whether activation of the PI3K/Akt pathway
was responsible for the anchorage-independent growth
affected by lipocalin 2 overexpression in 4T1 cells, we
inactivated the PI3K/Akt pathway with LY294002. The
colony forming abilities of both lipocalin 2-overexpres-
sion 4T1 cells and the Mock cells were unaffected by inhi-
bition of the PI3K/Akt pathway (Figure 6), indicating that
the anchorage-independent growth caused by lipocalin 2
was not associated with the PI3K/Akt pathway.
Discussion
Breast cancer is a major problem for public health. In
women with breast cancer, it is not the primary tumor but
its metastasis to distant sites that is the ultimate cause of
death. Therefore, the identification of new markers as well
as the definition of new therapeutic targets is of critical
importance [24].
In our paper, the findings demonstrated that lipocalin 2
didn't affect the proliferation and anchorage-independent
growth of 4T1 cells in vitro and primary tumor weight in
vivo. Some studies about the roles of lipocalin 2 in cancer
progression supported our findings. For example, lipoca-
lin 2 expression level was found to be significantly higher
in oesophageal squamous cell carcinoma (ESCC) than in
normal mucosa. However, no significant association was
observed between lipocalin 2 expression and cell prolifer-
ation [25]. Moreover, another report also indicated that
lipocalin 2 was possibly involved in invasion of tumor
cells by regulating activity of MMP-9 and MMP-2, but was
not apparently related with division and proliferation of
tumor cells in SHEEC [12]. These studies suggested that
lipocalin 2 expression wasn't related with cancer prolifer-
ation.
Effects of lipocalin 2 on migration and invasion of 4T1 cells Figure 3
Effects of lipocalin 2 on migration and invasion of 4T1 cells. (A) Transmembrane cell migration. Motility of Mock and 
LCN2 cells was evaluated by Transwell migration assays. Relative cell migration was determined by the number of the migrated 
cells normalized to the total number of the cells adhering to well and the value from Mock cells was arbitrarily set at 1. (B) The 
relative invasion assays for lipocalin 2 overexpressed 4T1 cells. *P < 0.05, **P < 0.01.Journal of Experimental & Clinical Cancer Research 2008, 27:83 http://www.jeccr.com/content/27/1/83
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The process of tumor metastasis is a multistage event
involving local invasion and destruction of intercellular
matrix, intravasation into blood vessels, lymphatics or
other channels of transport, survival in the circulation,
extravasation out of the vessels in the secondary site and
growth in the new location [26]. In our study, although
the effects of lipocalin 2 on proliferation and anchorage-
independent growth of 4T1 cells were not significant, our
results from cell migration and invasion analysis indi-
cated that cell mobility was significantly higher in the
LCN2 cells than Mock cells, denoting an aggressive phe-
notype in tumor cells. Because increased malignant cell
motility has been associated with enhanced metastatic
potential in animal as well as human tumors [27], we fur-
ther did an experiment in vivo. As we predicted, the results
revealed that lipocalin 2 overexpression enhanced the
metastasis of 4T1 cells in BALB/c mice. This enhancement
suggested that lipocalin 2 might provide some advantage
to the cancer cells growing in the complex cellular envi-
ronment of the host tissues. Although the precise nature
of this advantage remains to be determined, previous
studies have argued to suggest that lipocalin 2 may mod-
ulate the interactions with immune system. For example,
it has been demonstrated that lipocalin 2 synthesis is
highly induced in epithelial cells in both inflammatory
and neoplastic colorectal diseases [28]. Lipocalin 2 may
Effects of lipocalin 2 on tumor formation and lung metastases Figure 4
Effects of lipocalin 2 on tumor formation and lung metastases. Murine were killed and analyzed at the end of 30 days 
post tumor implantation. (A) Upper panels: representative photos of the lungs. The arrows point to the metastatic nodules in 
lungs. Lower panels: the average numbers of lung metastatic nodules. (B) Primary tumor weights. (C) Upper panels: semiquan-
titative RT-PCR analysis of lipocalin 2 expression in primary tumors. Lower panels: quantitation of lipocalin 2 was performed 
after normalization with the β-actin. *P < 0.05, **P < 0.01.Journal of Experimental & Clinical Cancer Research 2008, 27:83 http://www.jeccr.com/content/27/1/83
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Lipocalin 2 promotes breast cancer cell migration through suppressing PI3K/Akt pathway Figure 5
Lipocalin 2 promotes breast cancer cell migration through suppressing PI3K/Akt pathway. (A) Upper panels: the 
expression and activation of Akt detected by immunoblotting with anti-Akt, anti-p-Akt Ser (473), and anti-p-Akt Thr (308) anti-
bodies. Lower panels: quantitation of these blots after normalization with the β-Actin blot. (B) Upper panels: the expression 
and activation of PTEN detected by immunoblotting. Lower panels: quantitation of these blots after normalization with the β-
Actin blot. (C) Upper panels: expression and activation of MAPK detected by immunoblotting. Lower panels: quantitation of 
these blots after normalization with the β-Actin blot. (D) The migration ability of 4T1 cells was enhanced by LY294002. (E) The 
invasion ability of 4T1 cells was enhanced by LY294002. *P < 0.05, **P < 0.01. p-MAPK, phosphor-MAPK Thr202/Tyr204; 
MAPK, mitogen-activated protein kinase; p-PTEN, phosphor-PTEN Ser380/Thr382/383; PTEN, phosphatase and tensin 
homolog; PI3K, phosphoinositide-3 kinase.Journal of Experimental & Clinical Cancer Research 2008, 27:83 http://www.jeccr.com/content/27/1/83
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also bind other lipophilic mediators of inflammatory
responses and extracellular matrix-degrading proteinases,
which jointly cause invasion and aggravation. Our results
suggested that lipocalin 2 was a key modulator for breast
cancer cells metastasis.
The previous report indicated that lipocalin 2 could
diminish migration and invasion of 4T1-Ras-transformed
mesenchymal tumor cell line [29]. And a study by
Venkatesha  et al. demonstrated that lipocalin 2 could
antagonize the proangiogenic action of Ras-transformed
cells [2]. These results indicated that lipocalin 2 was an
epithelial inducer in Ras malignancy and a suppressor of
metastasis. In contrast, our results showed that lipocalin 2
promoted lung metastasis in non-Ras-induced 4T1 cells.
Therefore, the effect of lipocalin 2 on tumor metastasis
depended on the tumor-type specificity. It was necessary
to define the roles and molecular mechanisms of lipocalin
2 in given cancer metastasis. To gain a better understand-
ing of these metastasis effects, the molecular mechanisms
by which lipocalin 2 affected cell migration and invasion
should be studied. The previous study reported that the
Ras-MAPK and the PI3K/Akt pathways were critical for the
maintenance of EMT (epithelial to mesenchymal transi-
tion) in 4T1-Ras cells [29]. It also demonstrated that
lipocalin 2 inhibited Ras-mediated invasion/migration by
up-regulating E-cadherin through an inhibition of MAPK
signaling. But our study found that overexpression of
lipocalin 2 could not affect the MAPK pathway. It is gen-
erally accepted that the PI3K/Akt axis promotes tumori-
genesis by increasing the survival capacity of cancer cells
[30]. However, Gu et al. demonstrated the PI3K/Akt path-
way had no effect on anchorage-independent growth of
4T1 cells [31]. Here, we also found the colony forming
abilities of both Mock cells and LCN2 cells were unaf-
fected by inhibition of the PI3K/Akt pathway, indicating
this reduction of Akt activity caused by lipocalin 2 had no
effect on survival of 4T1 cells. Besides that, some recently
published evidence indicated that Akt could block breast
cancer cell migration and invasion [31-34]. In this study,
we found that the overexpression of lipocalin 2 increased
migration and invasion of non-Ras-induced 4T1 cells and
inhibited the PI3K/Akt pathway in non-Ras-induced 4T1
cells. Altogether, lipocalin 2 is associated with breast can-
cer cells migration and invasion occurred, at least partly,
through the PI3K/Akt pathway, although further studies
will be necessary to confirm this finding.
Conclusion
This study demonstrated that lipocalin 2 overexpression
could increase cell migration, invasion, and lung metasta-
sis in 4T1 murine breast cancer cells. The molecular mech-
anism underlying the lipocalin 2-mediated migration and
invasion was found to be inhibition of the PI3K/Akt path-
way. To our knowledge, this report is the first to elucidate
the involvement of lipocalin 2 and mechanisms by which
it influences the malignant properties of breast cancer
cells.
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